The possibility of re-infection by the young coronavirus Researchers in Britain are calling on volunteers who have already been infected with covid-19 to be exposed to the virus a second time to test the immune system’s response and determine if they will get a second time.
In February, Britain became the first country in the world to approve special surveys in which volunteers were voluntarily exposed to COVID-19 in order to advance the investigation for the disease caused by the coronavirus.
The new study was launched today, and differs from the study announced in February, as it seeks to re-infect people who have already contracted COVID-19 in an effort to deepen understanding the mechanism of immunity and not the infection of humans for the first time.
“The information from this research will allow us to better design vaccines and treatments and also to understand if people are protected after being infected with COVID-19 and for how long, “said Ellen Maxine, a vaccination specialist at Oxford University who is leading the study, according to AMBE.
She added that the research will help to understand what are the mechanisms that protect against infection for the second time.
Scientists have been using this type of research for decades to learn more about diseases such as malaria, influenza, typhoid and cholera, but also to develop treatments and vaccines against these diseases.
The first stage of the research will seek to determine the minimum dose of coronavirus, which is required for its reproduction in approximately 50% of the participants, while asymptomatic will also be studied.
In the second stage, which will start in the summer, different volunteers will be infected with the fixed dose that will result from the first stage.
In the first phase, at least 64 healthy participants, aged 18-30 who were infected with the coronavirus three months ago, will be infected for the second time with the original strain SARS-CoV-2.
They will remain in quarantine for at least 17 days and will be monitored, while anyone with symptoms will receive treatment with Regeneron monoclonal antibodies.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
